P
7.58
-0.53 (-6.54%)
| 前收盘价格 | 8.11 |
| 收盘价格 | 8.01 |
| 成交量 | 90,202 |
| 平均成交量 (3个月) | 268,022 |
| 市值 | 195,608,704 |
| 预期市盈率 (P/E Forward) | 11.78 |
| 价格/销量 (P/S) | 2.84 |
| 股市价格/股市净资产 (P/B) | 2.54 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2026 |
| 营业毛利率 | -42.99% |
| 营业利益率 (TTM) | -76,248.27% |
| 稀释每股收益 (EPS TTM) | -2.87 |
| 季度收入增长率 (YOY) | -99.80% |
| 总债务/股东权益 (D/E MRQ) | 60.30% |
| 流动比率 (MRQ) | 6.62 |
| 营业现金流 (OCF TTM) | -58.52 M |
| 杠杆自由现金流 (LFCF TTM) | 6.86 M |
| 资产报酬率 (ROA TTM) | -17.83% |
| 股东权益报酬率 (ROE TTM) | -50.81% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Precision BioSciences, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.50 |
|
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 10.94% |
| 机构持股比例 | 42.73% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Aberdeen Group Plc | 31 Mar 2026 | 2,230,178 |
| Empery Asset Management, Lp | 31 Mar 2026 | 1,968,879 |
| Octagon Capital Advisors Lp | 31 Dec 2025 | 1,917,995 |
| Bleichroeder Lp | 31 Mar 2026 | 1,662,500 |
| Boothbay Fund Management, Llc | 31 Dec 2025 | 1,066,050 |
| Driehaus Capital Management Llc | 31 Mar 2026 | 995,371 |
| Lynx1 Capital Management Lp | 31 Mar 2026 | 985,113 |
| Alyeska Investment Group, L.P. | 31 Dec 2025 | 798,000 |
| Affinity Asset Advisors, Llc | 31 Mar 2026 | 597,946 |
| Sphera Funds Management Ltd. | 31 Dec 2025 | 396,116 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合